Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

An ex­per­i­men­tal pill from Servi­er Phar­ma­ceu­ti­cals showed po­ten­tial­ly prac­tice-chang­ing re­sults in a nar­row group of brain can­cer pa­tients, cut­ting the risk of their can­cers pro­gress­ing by 61%, ac­cord­ing to a late-stage clin­i­cal tri­al.

The drug, vo­rasi­denib, is a pre­ci­sion med­i­cine that on­ly works in cer­tain peo­ple whose can­cer car­ries mu­ta­tions in one of two genes called IDH1/2. Doc­tors hope that the ther­a­py will de­lay the need for chemother­a­py or ra­di­a­tion, which are of­ten used to com­bat re­laps­es in pa­tients who’ve pre­vi­ous­ly un­der­gone surgery to re­move brain tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA